Novo Nordisk spotlights future innovations within diabetes as insulin sales recede
Novo Nordisk has two types of insulin in the works which would finally bring some much-needed innovation to the area, says Novo exec Camilla Sylvest, pointing out that the area has not received enough attention for a while.
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
A number of bleak years for pharmaceutical firm Novo Nordisk’s insulin business, particularly in the US, have been replaced by a bright outlook.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
